Product
Cyclophosphamide/Rituximab
1 clinical trial
2 indications
Indication
Multiple SclerosisIndication
Relapsing-RemittingClinical trial
Optimal Conditioning Regimen Protocol for Autologous Hematopoietic Stem Cell Transplantation of Relapsing Remitting Multiple SclerosisStatus: Withdrawn, Estimated PCD: 2027-07-01